Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis : results of the multicenter HOVON 104 trial by Minnema, Monique C et al.
2274 haematologica | 2019; 104(11)
Received: December 6, 2018.
Accepted: March 18, 2019.
Pre-published: March 28, 2019.
©2019 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-
mercial purposes is not allowed without permission in writing
from the publisher.
Correspondence: 
MONIQUE C. MINNEMA
m.c.minnema@umcutrecht.nl
Haematologica 2019
Volume 104(11):2274-2282
ARTICLE Plasma Cell Disorders
doi:10.3324/haematol.2018.213900
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/104/11/2274
Ferrata Storti Foundation
This prospective, multicenter, phase II study investigated the use offour cycles of bortezomib-dexamethasone induction treatment, fol-lowed by high-dose melphalan and autologous stem cell transplanta-
tion (SCT) in patients with newly diagnosed light chain amyloidosis. The
aim of the study was to improve the hematologic complete remission (CR)
rate 6 months after SCT from 30% to 50%. Fifty patients were enrolled and
72% had two or more organs involved. The overall hematologic response
rate after induction treatment was 80% including 20% CR and 38% very
good partial remissions (VGPR). Fifteen patients did not proceed to SCT for
various reasons but mostly treatment-related toxicity and disease-related
organ damage and death (2 patients). Thirty-one patients received melpha-
lan 200 mg/m2 and four patients a reduced dose because of renal function
impairment. There were no deaths related to the transplantation procedure.
Hematologic responses improved at 6 months after SCT to 86% with 46%
CR and 26% VGPR. However, due to the high treatment discontinuation
rate before transplantation the primary endpoint of the study was not met
and the CR rate in the intention-to-treat analysis was 32%. Organ respons-
es continued to improve after SCT. We confirm the high efficacy of borte-
zomib-dexamethasone treatment in patients with AL amyloidosis.
However, because of both treatment-related toxicity and disease character-
istics, 30% of the patients could not proceed to SCT after induction treat-
ment. (Trial registered at Dutch Trial Register identifier NTR3220).
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ABSTRACT
Introduction
Light chain (AL) amyloidosis is a potentially fatal disor-
der caused by a small monoclonal population of plasma
cells in the bone marrow, which synthesize monoclonal
light chains. The light chains are considered toxic and
aggregate into amyloid fibrils. These fibrils form extracel-
lular deposits in one or more vital organs, most frequently
in the kidneys, heart and liver as well as in the peripheral
and autonomic nervous systems.1
The main goal of treatment is to reduce the supply of the
amyloidogenic monoclonal light chains rapidly and to
achieve a very good partial response (VGPR) or a complete
hematologic response (CR).2 Achieving a hematologic
response is closely related with survival. This has been
demonstrated following both high-dose and standard-dose
chemotherapy.2,3 Organ responses are also induced in
patients with prolonged hematologic responses. 
High-dose melphalan (HDM) followed by autologous
SCT (auto-SCT) is considered the most effective treat-
ment for selected patients with AL amyloidosis.4
However, this treatment is only feasible in around 20%
or fewer of newly diagnosed patients. Due to more strict
selection criteria for eligibility for transplantation, the
treatment-related mortality of auto-SCT has decreased to
below 5% and transplanted patients have an excellent
survival after their transplant.5-7
In the previous HOVON (Haemato-Oncology
Foundation for Adults in the Netherlands) 41 study we
examined a two-step approach consisting of non-inten-
sive induction therapy followed by HDM and auto-SCT.8
Although the vincristine-adriamycin-dexamethasone
(VAD) induction treatment was considered too toxic, the
survival of patients was good with a median survival of 8
years from registration and, for the transplanted patients,
a median survival of 10 years from the date of transplan-
tation. Other retrospective single-center studies have also
examined the value of various induction regimens before
HDM and auto-SCT and concluded that induction thera-
py is associated with a better overall survival (OS), with
possibly the greatest benefit for patients with >10% bone
marrow plasma cell infiltration.9,10
Bortezomib (Velcade), a proteasome inhibitor fre-
quently used in first-line and relapse treatment in patients
with multiple myeloma (MM), has been given to newly
diagnosed and relapsed AL amyloidosis patients in most-
ly retrospective and only one prospective multicenter
study. The hematologic response rate to bortezomib was
excellent, ranging from 50% to 80% with a CR rate from
25% to 47%; furthermore, the CR occurred rapidly, espe-
cially when the drug was administered bi-weekly.11-13
Common toxicities included thrombocytopenia, periph-
eral sensory neuropathy, neuropathic pain, hypotension
and peripheral edema. 
Considering the potent effect of bortezomib in relapsed
AL amyloidosis patients and the improvement in response
rates achieved when used as first-line treatment in MM
patients, we hypothesized that the use of this drug, in
combination with auto-SCT, could also improve the
response rates of AL amyloidosis patients. Because the CR
rate, in particular, is closely related to progression-free sur-
vival (PFS), OS and organ responses, the current trial inves-
tigated the efficacy of  induction treatment consisting of
bortezomib and dexamethasone followed by HDM and
auto-SCT to improve the CR rate after auto-SCT.
Methods 
The HOVON 104 study was conducted in 15 centers in
the Netherlands, Germany, and Belgium. The trial started
with a randomized, phase III design but due to slow
accrual the dexamethasone arm closed after including
seven patients and the trial continued as a single-arm,
phase II study. 
Patients with biopsy-proven, systemic, AL amyloidosis,
aged between 18-70 years, with detectable M-protein
and/or involved free light chains (FLC) >50 mg/L, World
Health Organization (WHO) Performance Status 0-2, and
New York Heart Association (NYHA) stage 1-2 were
included. Eligibility criteria at inclusion corresponded to
eligibility criteria for auto-SCT with the exception of
measurement of cardiac ejection fraction. Major exclu-
sion criteria were concurrent MM defined as Salmon-
Durie stage II or III, previous treatment of plasma cell
dyscrasia, symptomatic orthostatic hypotension, sympto-
matic effusions, a N-terminal pro-brain natriuretic pep-
tide (NT-proBNP) level >5,000 pg/mL, troponin T >0.06
µg/L or troponin I >2 x upper limit of normal, estimated
glomerular filtration rate (eGFR) <30 mL/min/1.73 m2,
National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI CTCAE) sensory peripheral neu-
ropathy > grade 2 or > grade 1 with pain and motor
peripheral neuropathy > grade 2 (see the Online
Supplement for the complete list). Inclusion and exclusion
criteria were also established for stem cell mobilization.
Inclusion criteria comprised a WHO Performance Status
0-2, NYHA stage 1-2, and ejection fraction >45%. The
exclusion criteria are listed in the Online Supplement. The
study was approved by the ethics committee of all partic-
ipating hospitals and the University Medical Center
Utrecht (Institutional Review Board n. 10-426). All proce-
dures were conducted in compliance with the
Declaration of Helsinki. Written informed consent to par-
ticipation in the study was provided by all patients
(EudraCT number 2010-021445-42).
Treatment design
Four 21-day cycles of induction treatment were given. The
cycles consisted of bortezomib subcutaneously (sc) 1.3 mg/m2
on days 1, 4, 8, and 11 and dexamethasone 20 mg orally on each
day of bortezomib administration and the following day. Dose
adjustments are described in the Online Supplement. Stem cell
mobilization began within 4-6 weeks after the start of the last
induction cycle using granulocyte colony-stimulating factor 10
mg/kg divided in two doses, given for 5 days. The melphalan
dosage was 200 mg/m2 given in 2 days. Patients with an eGFR
<40 mL/min/1.73 m2 were given 100 mg/m2 melphalan.
Hematologic response was measured after each induction cycle
and it was planned that all patients would receive HDM.
Patients not responding to induction treatment could proceed
directly to stem cell mobilization and auto-SCT if eligibility cri-
teria were met. 
Hematologic and organ response criteria
Organ involvement and hematologic and organ responses
were evaluated according to the consensus criteria of the
International Society of Amyloidosis published in 2005 with
some modifications such as the addition of a VGPR category and
addition of NT-proBNP for cardiac response14,15 (see the Online
Supplement).
Both hematologic and organ responses were measured after
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each induction cycle, after stem cell mobilization and before auto-
SCT, and thereafter every 3 months for 5 years after registration.
In addition, patients could participate in a side study with meas-
urement of minimal residual disease by flow cytometry when a
CR was reached or 6 months after auto-SCT. Flow cytometry was
performed centrally with a sensitivity level of 10-5. Details are pro-
vided in the Online Supplement.
Statistical design and endpoints
The primary endpoint was the efficacy of bortezomib-dexam-
ethasone induction treatment followed by HDM and auto-SCT,
measured as the proportion of patients with a CR at 6 months
after auto-SCT.  The secondary endpoints and analysis of the
effect of baseline characteristics on auto-SCT, OS and PFS are
described in the Online Supplement.
Results
Patients’ characteristics
Between March 2012 and April 2016, 50 patients were
enrolled in the phase II part of the trial. Table 1 summa-
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Table 1. Baseline characteristics of 50 patients, separated for groups that did or did not proceed to autologous stem cell transplantation. 
Characteristic                                       Patients who proceeded to auto-SCT         Patients who did not proceed to auto SCT                All patients
                                                                                   (N = 35)                                                         (N = 15)                                            (N = 50)
Age (years), median (IQR)                                                59 (50-63)                                                                  60 (53-63)                                                   59 (51-63)
Sex (female), n (%)                                                              14 (40%)                                                                      6 (40%)                                                      20 (40%)
WHO performance status, n (%)
0                                                                                                17 (49%)                                                                      6 (40%)                                                      23 (46%)
1                                                                                                16 (46%)                                                                      5 (33%)                                                      21 (42%)
2                                                                                                  1 (3%)                                                                        4 (27%)                                                       5 (10%)
Clonal disease, n (%)
Lambda                                                                                  27 (77%)                                                                     13 (87%)                                                     40 (80%)
Kappa                                                                                       8 (23%)                                                                       2 (13%)                                                      10 (20%)
Involved FLC level, median (IQR)                                  167 (63-341)                                                              205 (64-493)                                                181 (73-35)
dFLC, median (IQR)                                                         214 (103-342)                                                             212 (68-461)                                               213 (80-397)
Number of patients with dFLC ≥ 180 mg/L,                     17 (49%)                                                                      8 (53%)                                                      25 (50%)
median (IQR)
% plasma cells in bone marrow, median (IQR)              6 (4-11)                                                                        5 (2-8)                                                        6 (0-33)
Number of patients with ≥ 10% plasma cells,                12 (34%)                                                                      2 (13%)                                                      14 (28%)
median (IQR)
Median number of organs involved, n (%)                        2 (1-3)                                                                         2 (1-3)                                                         2 (1-3)
Number of  organs involved
≥ 2                                                                                            26 (74%)                                                                     10 (67%)                                                     36 (72%)
≥ 3                                                                                            12 (34%)                                                                      7 (47%)                                                      19 (38%)
Organ involvement, n (%)
Kidney                                                                                     29 (83%)                                                                     12 (80%)                                                     41 (82%)
Heart                                                                                       23 (66%)                                                                     10 (67%)                                                     33 (66%)
Nervous system                                                                     4 (11%)                                                                       3 (20%)                                                      7 (14%)
Gastrointestinal system                                                      4 (11%)                                                                        0 (0%)                                                        4 (8%) 
Liver                                                                                          8 (23%)                                                                       5 (33%)                                                      13 (26%)
Soft tissues                                                                              5 (14%)                                                                       3 (20%)                                                      8 (16%) 
Mayo classification, n (%)
I                                                                                                12 (34%)                                                                      4 (27%)                                                      16 (32%)
II                                                                                               10 (29%)                                                                      6 (40%)                                                      16 (32%)
III                                                                                             12 (34%)                                                                      5 (33%)                                                      17 (34%)
NYHA stage, n (%)
I                                                                                                22 (63%)                                                                      6 (40%)                                                      28 (56%)
II                                                                                               12 (34%)                                                                      9 (60%)                                                      21 (42%)
NT-proBNP level (ng/L), median (IQR)                      675 (166-1638)                                                         1110 (264-2292)                                          832 (204-1638)
Echo cardiography, median (IQR)
Mean left ventricular wall thickness                          12 mm (11-15)                                                          13 mm (12-14)                                           13 mm (11-15)
Ejection fraction                                                                63% (55-71)                                                               58% (53-66)                                                60% (55-68)
Diastolic dysfunction                                                       60% present                                                              60% present                                               60% present
eGFR  (mL/min/1.73 m2), median (IQR)                         68 (58-87)                                                                  90 (60-95)                                                   72 (59-90)
Renal stage
I                                                                                                12 (34%)                                                                      8 (53%)                                                      20 (40%)
II                                                                                               19 (54%)                                                                      6 (40%)                                                      25 (50%)
III                                                                                              4 (11%)                                                                        1 (7%)                                                        5 (10%)
Auto-SCT: autologous stem cell transplantation; WHO: World Health Organization; FLC: free light chain; dFLC: difference between involved and uninvolved free light chains;
NYHA: New York Heart Association; NT-proBNP: N-terminal pro-brain natriuretic peptide; eGFR: estimated glomerular filtration rate.
rized the patients’ characteristics separately for those
who proceeded to auto-SCT and those who did not. The
median age of all the patients included was 59 years
[interquartile range (IQR), 51-63]. The median number of
organs involved was two (range, 1 to 5). Two or more
organs were involved in 36 patients (72%) and three or
more in 19 (18%). The kidney was the organ most fre-
quently involved, with renal disease in 82% of patients,
followed by the heart (in 66% of patients) and liver (in
26% of patients). The median eGFR at inclusion was 72
mL/min/1.73 m2 (IQR, 59-90) and 20, 25 and 5 patients
had renal stage I, II or III, respectively.16 Mayo cardiac
stage was I, II and III for 16, 16 and 17 patients, respec-
tively (data unavailable for 1 patient).17 The initial median
NT-proBNP level was 832 pg/mL (IQR, 204-1638).
Echocardiography data were available for 47 patients. 
Fourteen patients (28%) had a plasma cell infiltration of
≥10% in the bone marrow. Most patients presented with
λ light chains (80%). The median concentration of
involved FLC was 180 mg/L (IQR, 73-352) for λ light
chains and 169 mg/L (IQR, 61-879) for κ light chains. The
median difference between involved and uninvolved FLC
(dFLC) was 213 mg/L (IQR, 80-397) and 50% of patients
had a dFLC ≥180 mg/L. Of note, seven patients were
included without an M-protein or dFLC value that could
qualify them for the PR or VGPR category and three of
these patients also did not have a urine protein elec-
trophoresis >0.1 g/day. 
In the group of seven patients enrolled in the dexa -
methasone arm of the closed, phase III part of the trial
one patient was not eligible. The median age of the other
six patients was 57 years and these patients’ other base-
line characteristics were also comparable to those of the
50 patients in the phase II part (data not shown). Three
patients underwent auto-SCT and the estimated 3-year
PFS was 83%. These six patients are not included in this
final analysis.
Treatment characteristics 
All patients started with induction treatment. Most
patients (88%) received four cycles of bortezomib-dexa -
methasone, two patients received three cycles, two
patients received only two cycles and two patients had to
discontinue induction treatment after the first cycle. Half
of the patients had dose modifications in the adminis-
tered cycles as prescribed per protocol: in 50% of patients
the bortezomib dose was modified and in 44% the dexa -
methasone dose was modified. The reasons for dose
modifications for bortezomib were mostly neurotoxicity,
both sensory and autonomic neuropathy (9 patients) and
infection (3 patients) and for dexamethasone heart failure
(4 patients), edema (3 patients), infection (3 patients) and
myopathy (2 patients).
Eleven patients did not have their stem cells collected
after induction therapy. Five patients did not fulfill the eli-
gibility criteria, including two patients who stopped
induction due to progressive heart failure and kidney fail-
ure. Two patients died, one during the first cycle of induc-
tion, three patients experienced bortezomib-related toxi-
city and were taken off the trial during induction treat-
ment (1 patient with bronchial hyperreactivity, 1 patient
with gastrointestinal necrosis and 1 patient with NCI
CTCAE grade 4 sensory neuropathy) and one patient
refused stem cell collection.
The median number of stem cells collected was 6.3x106
CD34/kg (IQR, 4.6-9.3). Ten patients needed 2 days of
apheresis and cyclophosphamide was given to nine
patients according to local policy. After stem cell collec-
tion, four patients did not proceed to HDM and stem cell
reinfusion. All four had clinical deterioration: two
patients developed symptomatic pleural effusions, one
patient started dialysis and one patient had several toxic-
ities, a worsening clinical condition and was taken off the
trial by decision of the treating physician.  
In total 35 patients (70%) received HDM and stem cell
reinfusion as an inpatient procedure. Thirty-one patients
were given a full dose of HDM, per protocol; in four
patients the melphalan dose was reduced to 100 mg/m2
because their eGFR was <40 mL/min/1.73 m2. All patients
engrafted without granulocyte colony-stimulating factor
support in a median time of 13 days for white blood cells
and 16 days for platelets. A CONSORT diagram summa-
rizes the treatment course of all 50 patients (Figure 1).
Based on a univariate logistic regression model we
could not identify a prognostic baseline characteristic
such as NYHA stage, NT-proBNP, Mayo stage, ≥10%
plasma cells, dFLC ≥180 mg/L, or number of involved
organs that was related to proceeding to auto-SCT after
induction therapy. As shown in Table 1 the baseline
Mayo stage was not statistically different between the
groups of patients who did or did not proceed to auto-
SCT (P=0.80). In the 35 patients who underwent auto-
SCT, 22 received full-dose bortezomib and 23 full-dose
dexamethasone. In contrast, in the 15 patients who did
not proceed to auto-SCT only three received full-dose
bortezomib and five full-dose dexamethasone. Because
troponin levels were only measured at baseline, a Mayo
stage assessment could not be calculated after induction
treatment or before auto-SCT. 
Hematologic responses 
Hematologic responses are summarized in Table 2. The
overall response rate (ORR) after induction treatment was
80%, which included the 38% of patients with a VGPR
and 20% with a CR. The median time to first response
was 28 days (IQR, 21-43) and the median time to best
response was 67 days (IQR, 28-240). Eighty percent of the
responses were detected within the first 3 months after
starting treatment (Figure 2). Ten patients (20%) had a CR
after induction treatment and eight of them proceeded to
auto-SCT. Responses assessed 6 months after auto-SCT,
which was the primary endpoint of the study, improved
but were assessed in 35 patients only, since 15 patients
did not proceed to auto-SCT. In these 35 patients, the CR
rate doubled from 23% after induction treatment to 46%
at 6 months after auto-SCT. The ORR increased to 86%
at 6 months after auto-SCT. In the intention-to-treat
analysis the CR rate at 6 months after auto-SCT was 32%
and therefore the primary endpoint of the study was not
met. In the group of 15 patients who did not proceed to
auto-SCT, ten (67%) had a hematologic response. In uni-
variate logistic regression analyses a dFLC ≥180 mg/L and
bone marrow plasma cell infiltration ≥10% at diagnosis
were not related to the depth of the hematologic
response.
Flow cytometry 
Samples for flow cytometry were available at diagnosis
for 26 patients. Of this group, 20 patients proceeded to
auto-SCT. The median percentage of clonal plasma cells
Bortezomib induction and SCT in AL amyloidosis
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detected at baseline was 1.4% (range, 0.17-4.9). At 6
months after auto-SCT, samples were collected from
seven patients. Six of these patients had a CR and were
also negative for minimal residual disease. Additional
analyses were performed, such as those previously
reported by Perez-Persona et al. who described that a
ratio of clonal plasma cells within the total bone marrow
plasma cells (aPC/BMPC) ≥95% had prognostic value for
progression to MM in patients with monoclonal gam-
mopathy of unknown significance and smoldering MM.18
In the current study patients with aPC/BMPC ≥95% at
baseline had a shorter PFS (hazard ratio 8.44, 95% confi-
dence interval: 1.05-67.96) and a lower probability of pro-
ceeding to auto-SCT; however, given the small sample
size this was not statistically significant (odds ratio 0.16,
95% confidence interval: 0.02-1.67).
Organ responses 
Organ responses were already seen after induction
treatment and improved after HDM plus auto-SCT and
are summarized in Figure 3 for both patients who pro-
ceeded to auto-SCT and those who did not. The rate of
M.C. Minnema et al.
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Table 2. Hematologic response rates during the different treatment phases. 
                                               After induction therapy          +6 months after  auto-SCT        +12 months after auto-SCT       +24 months after auto-SCT
                                                                                                             (n=35)                                        (n=34)                                       (n=33)
Hematologic response (intention to treat) 
≥PR (ORR)                                               83% (80%)                                       86% (60%)                                          89% (60%)                                        91% (60%)
≥VGPR                                                        66% (58%)                                       72% (50%)                                          77% (52%)                                        76% (50%)
CR                                                                23% (20%)                                       46% (32%)                                          56% (38%)                                        58% (38%)
                                                                                                                                                                                                                                                                     
Median time to first response                28 days                                                                                                                                                                               
Median time to best response                67 days                                                                                                                                                                               
*The first percentage concerns patients who underwent autologous stem cell transplantation (35 in total), the second percentage between brackets is the response rate assessed
in an intention-to-treat analysis. Auto-SCT: autologous stem cell transplantation; PR: partial response; ORR: overall response rate; VGPR: very good partial response; CR: complete
response.
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram of
the 50 patients included in the trial. HDM: high-dose melphalan; G-CSF: granu-
locyte colony-stimulating factor.
kidney responses improved from 24% to 69% at 2 years
after auto-SCT and that of cardiac responses from 24% to
78%. In intention-to-treat analysis 61% of patients
achieved a renal response, 72% a cardiac response and
62% a liver response. During the HDM and auto-SCT
procedure two patients had a deterioration of their renal
function, defined as a decrease of 25% in eGFR, which
persisted during the follow-up. The median time to first
organ response was 222 days for the heart (IQR, 125-395)
and 318 days (IQR 91-615) for the kidney. Organ progres-
sion was seen in six of 33 patients with cardiac involve-
ment, 13 out of 41 patients with kidney involvement, and
three of 13 patients with liver involvement. 
During the study new renal response criteria were
developed (≥30% decrease in proteinuria or drop of pro-
teinuria <0.5 g/day in the absence of renal progression,
defined as a ≥25% decrease in eGFR). According to these
criteria 14 patients (48%) who proceeded to auto-SCT
had a renal response after induction treatment and this
increased to 22 patients (76%) after auto-SCT (Figure 3).  
Patients with a deep hematologic response (CR/VGPR)
at 6 months after auto-SCT and at subsequent time-
Bortezomib induction and SCT in AL amyloidosis
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Figure 4. Overall and progression-free survival of the total cohort of patients and the 35 patients who underwent autologous stem cell transplantation. (A)
Progression-free and overall survival from date of registration in the trial for the 50 patients included. (B) Progression-free survival from autologous stem cell trans-
plantation of the 35 transplanted patients according to response achieved after induction therapy. PFS: progression-free survival; OS: overall survival; PR: partial
remission; VGPR: very good partial remission.
Figure 3. Organ responses depicted separately for patients who proceeded to
autologous stem cell transplantation or not. Organ responses were assessed
according to consensus criteria after induction and as best responses achieved
during study treatment and follow-up. Auto-SCT: autologous stem cell transplan-
tation.
Figure 2. Response rates following the initiation of treatment. The upper line
represents the time to first response, defined as partial response or better, while
the lower line represents the time to first complete response. PR: partial
response; CR: complete response.
points had a higher renal response rate (72% vs. 28%,
P=0.03). Although more patients in this group also had a
higher cardiac response rate (65% vs. 35%), the difference
was not statistically significant for cardiac response at any
time-point after auto-SCT. 
Overall survival and progression-free survival  
The median follow-up of the 43 patients still alive is
38.3 months (IQR, 34-46) while that of all 50 patients is
36.9 months (IQR, 29-46). Five patients died during the
follow-up, in most cases due to amyloid-related organ
failure. None of the transplanted patients has died.
Kaplan-Meier PFS curves for all 50 patients and the 35
transplanted patients are shown in Figure 4. The median
OS and PFS were not reached. The 3-year estimated OS
and PFS rates are 86% and 63%,  respectively.  In total
seven patients had progression of their plasma cell
dyscrasia after auto-SCT, including one patient with a
previous CR, three with a VGPR, two with a PR and one
patient who did not have any response. None of the eight
patients with a CR before auto-SCT has progressed,
whereas eight of the patients who had not achieved a CR
prior to auto-SCT have done so (P=0.13). Using univari-
ate Cox regression prognostic baseline characteristics,
such as type of hospital (high vs. low number of included
patients), eGFR (>30 and <50 vs. ≥50 mL/min/1.73 m2,
NYHA class (I vs. II), NT-proBNP (as a continuous vari-
able), plasma cell infiltration (<10% vs. ≥10%), dFLC
<180 mg/L vs. ≥180 mg/L, number of organs involved (≤2
vs. >2), Mayo stage, nervous system involvement and car-
diac involvement were tested but none of these variables
was statistically related to OS.
Adverse events and mortality 
Adverse events were commonly seen during induction
treatment in all patients. The most frequent adverse
events seen during induction treatment are summarized
in Table 3. The most commonly experienced adverse
events were neurotoxicity, gastrointestinal symtpoms,
infections and cardiac disorders. Although dizziness,
orthostatic hypotension and syncope may also have car-
diac origins, all these events were grouped together as
autonomic neuropathic events if no cardiac cause, such as
arrhythmias or deterioration in ejection fraction, was
detected. In total, 10% of patients experienced autonom-
ic neuropathy and 34% had sensory neuropathy related
to bortezomib. Interestingly, patients with nervous sys-
tem involvement at the start of therapy did not require
more dose adjustments for bortezomib compared to
patients without nervous system involvement. No
engraftment syndrome was seen after auto-SCT.
Overall, 47 serious adverse events were reported in 29
patients, 34 during induction treatment, three during
stem cell mobilization and ten following 30 days after
HDM and auto-SCT. The serious adverse events were
mostly due to hospitalization (81%) and 28 were consid-
ered related to the treatment. Twenty-nine serious
adverse events resolved completely, the others were
ongoing. Two patients died during the study treatment
phase. One patient had a sudden cardiac death during the
first induction cycle, probably related to the cardiac amy-
loidosis, and one patient died due to hepato-renal syn-
drome after receiving four cycles of induction treatment.
There were no cases of transplant-related mortality. 
Discussion
The aim of the current prospective, multicenter study
was to investigate whether a more effective induction
regimen before HDM and auto-SCT could lead to better
outcomes in newly diagnosed AL amyloidosis patients.
Bortezomib is considered the first drug of choice both
because of the high response rates that it induces and the
fact that the responses tend to occur rapidly.19 We there-
fore hypothesized that using a two-step approach with
effective induction, starting immediately after diagnosing
and staging the AL amyloidosis, would not only improve
response rates after auto-SCT but would also rescue more
patients from amyloidosis-related organ damage. 
The ORR of 80%, with 20% CR, 38% VGPR and 22%
PR rates achieved after induction treatment, is indeed
comparable to that reported previously by Reece et al. in
relapsed AL amyloidosis patients (ORR 66.7%).13 In their
study a median of six cycles of bi-weekly bortezomib
was given compared to the four cycles of bi-weekly
bortezomib in the current study. In retrospective analyses
high response rates up to 80% have been reported in both
relapsed and newly diagnosed patients.11,12 We confirm a
rapid time to response with median times to first
response of 28 days and to best response of 67 days. 
Because of these fast and deep responses we expected
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Table 3. Percentages of the most common treatment-related adverse events of bortezomib-dexamethasone induction treatment.
Adverse event                                             Grade 1                    Grade 2                 Grade 3                    Grade 4                Grade 5                   Total
Nervous system, total                                               12                                    24                                12                                    2                                 -                                 50
- sensory PNP                                                              12                                    14                                 6                                     2                                 -                                 34
- autonomic (syncope, dizziness, 
orthostatic hypotension)                                        -                                      6                                  4                                     -                                 -                                 10
- motor                                                                            -                                      -                                  2                                     -                                 -                                  4
- neuropathic pain                                                       -                                      4                                  -                                      -                                 -                                   
Gastrointestinal (constipation, diarrhea,           na                                   30                                10                                    4                                 -                                 44
nausea, vomiting)
Infections                                                                    na                                   20                                10                                    -                                 -                                 30
Cardiac                                                                         na                                   12                                12                                    2                                2                                28
Metabolic/nutrition                                                   na                                   18                                 6                                     -                                 -                                 24
Fatigue                                                                         na                                   10                                 2                                     -                                 -                                 12
PNP: polyneuropathy, na:not assessed .
that a higher proportion of patients would be able to pro-
ceed to HDM and auto-SCT. However, the discontinuation
rate of 30% in the current study was similar to the 33%
observed in the previous HOVON 41 study in which VAD
induction therapy was given.8 The discontinuation rate
was substantially higher than those in two other prospec-
tive, single-center studies in which bortezomib-dexa -
methasone induction was given prior to HDM and auto-
SCT (0% and 14%).20,21 These differences could be
explained by different treatment designs; for example, in
the studies by Sanchorawala et al. and Huang et al., only
two cycles of bortezomib and dexamethasone induction
were given, instead of four. Perhaps more importantly,
these were single-center studies in large, experienced hos-
pitals, while the HOVON 104 trial was performed in 16
hospitals, which enrolled between one and eight patients
per site which may impair the quality of care. We therefore
think that our prospective data may better represent the
real-life outcome of patients following first-line AL amyloi-
dosis treatment. Although the discontinuation rate could
not be assessed in other retrospective studies because only
transplanted patients were included, these studies do sug-
gest that induction regimens can be beneficial in patients
by inducing deeper hematologic responses and better
OS.9,10
The reasons for 15 patients not proceeding to HDM
and auto-SCT were mostly non-eligibility according to
protocol, generally caused by symptomatic effusions and
poor  Performance Status. Some patients had borte-
zomib-related toxicity and in four patients the physician
decided that the patient should not proceed to auto-SCT
because of organ progression. The other toxicities seen
during induction treatment are summarized in Table 2.
These toxicities are comparable to those reported by
Reece et al., and most involved the gastrointestinal tract,
heart, and nervous system or were infections.13 Although
78% of patients received four cycles of bortezomib-dexa -
methasone, half of the patients needed dose reductions of
bortezomib and 44% needed reductions of dexametha-
sone. Due to the multiple organ dysfunctions typically
seen in AL amyloidosis, these patients do not tolerate the
same chemotherapy schedules as MM patients do. This
also seems to hold true for the “fittest” patients who
appeared to be eligible for auto-SCT at diagnosis.
Encouraging data from retrospective analyses illustrate
that other bortezomib-based regimens with reduced
doses of bortezomib to 1.0 m/m2 bi-weekly or 1.5 mg/m2
once weekly, combined with dexamethasone and
cyclophosphamide once weekly, could maintain the high
response rates but data on toxicity are limited.22,23 Once
weekly dosing of bortezomib could therefore be the pre-
ferred schedule in AL amyloidosis patients.
Using flow cytometry analysis at diagnosis we identi-
fied a negative association between  aPC/BMPC ≥95%
and PFS. In addition, we found that patients with
aPC/BMPC ≥95% had a lower probability of proceeding
to auto-SCT; however, due to our small sample size of 26
patients this was not statistically significant. A high ratio
of clonal plasma cells may reflect a more aggressive plas-
ma cell clone in the bone marrow and its prognostic value
has been determined in patients with monoclonal gam-
mopathy of undetermined significance and smoldering
MM.18 In patients with AL amyloidosis it has been
demonstrated that the persistence of 5% or more normal
plasma cells at diagnosis was related to OS, but due to the
shorter follow-up and excellent survival in the current
study, this association could not be confirmed.24 The
small sample size of the current study could perhaps be
the reason that we could not confirm that other baseline
characteristics, such as ≥10% plasma cells or a dFLC ≥180
mg/L, were negatively associated with survival.
There was no transplant-related mortality among the
35 patients who did receive HDM and auto-SCT and the
patients had an excellent outcome. This is remarkable,
because a previous prospective, multicenter study per-
formed by Jaccard et al. reported a high mortality rate of
24% related to the auto-SCT procedure. This study, like
ours, was also conducted in less experienced centers.25 It
could be speculated that the induction treatment before
HDM and auto-SCT functions as a selection mechanism
because only patients who are able to tolerate chemother-
apy proceed to high-dose treatment. Indeed, more
patients who received the full doses of the induction reg-
imen without dose adjustments proceeded to auto-SCT.
A randomized trial is needed to investigate the role of
induction therapy before auto-SCT. Interestingly, our
study demonstrates that HDM with auto-SCT is also pos-
sible for some patients with the highest cardiac Mayo risk
score of III, which was present in 34% of our study pop-
ulation. These patients did not experience more toxicity
than the other risk groups. However since the start of this
study new prognostic cardiac scoring systems have been
published which may improve the selection of patients
suitable for HDM and auto-SCT.26,27
The hematologic responses improved to 86% at 6
months after auto-SCT. In particular, the CR rate
increased steadily after auto-SCT. Since the quality of
response in AL amyloidosis patients is closely related to
survival this is a very important observation. The hema-
tologic responses after auto-SCT are less than those
reported in the two other prospective, single-center trials
but are better than those reported in larger retrospective
cohorts.7,20,21,28,29 However, due to the high discontinuation
rate before auto-SCT the primary endpoint of the study,
an improvement, in intention-to-treat analysis, of the CR
rate from 30% to 50% was not achieved. 
Organ responses were already detected after induction
therapy and the rates were 24%, 24% and 23% for the
kidney, heart and liver, respectively. The new renal
response criteria set was also prospectively evaluated and
was 27% after induction treatment.16 In total, six patients
developed kidney failure, defined as an eGFR <30
mL/min/1.73 m2: two of them had renal stage I at diagno-
sis, two had stage II and two had stage III. After auto-SCT
organ response rates continued to improve to 60%-80%
(Figure 3) which are comparable to those after auto-SCT
in previous reports.29
In conclusion, although the primary endpoint of the
study was not met, in this first, multicenter, prospective
trial with twice-weekly bortezomib, combined with
dexa methasone treatment, we documented a high hema-
tologic response rate of 80% in patients with newly diag-
nosed AL amyloidosis. However, these responses cannot
prevent amyloidosis-related organ failure and the treat-
ment-induced NCI-CTCAE grade 2 and higher gastroin-
testinal, cardiac, metabolic and neurotoxicity in more
than 70% of patients, leading to a high discontinuation
rate of 30% before auto-SCT. Possibly due to the unin-
tended selection of induction treatment prior to HDM
and auto-SCT, the transplants were performed without
Bortezomib induction and SCT in AL amyloidosis
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any mortality and improved the CR rate from 20% to
46% at 6 months after auto-SCT. 
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